CIK 0000949858 · Non-accelerated filer<br>Smaller reporting company
ACHIEVE LIFE SCIENCES, INC.
Sign in to watch- Ticker
- ACHV
- Exchange
- Nasdaq
- Industry
- In Vitro & In Vivo Diagnostic Substances
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 954343413
- Phone
- 425-686-1500
- Business address
- 22722 29TH DR. SE, SUITE 100, SEATTLE, WA, 98021
- Former names
- ONCOGENEX PHARMACEUTICALS, INC., SONUS PHARMACEUTICALS INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $175,177
- in 1 filing
Net −$175,177. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-04-18 | Goldberg Andrew D. CEO and President | Grant or award · Restricted Stock Unit (RSU) | +1,800,965 | 1,800,965 | ||
| 2026-04-18 | Goldberg Andrew D. CEO and President | Grant or award · Stock Option (right to buy) | +3,601,929 | 3,601,929 | ||
| 2026-04-18 | Goldberg Andrew D. CEO and President | Grant or award · Performance Restricted Stock Unit (PRSU) | +11,706,270 | 11,706,270 | ||
| 2026-01-28 | Rubinstein Mark Lawrence Chief Medical Officer | Grant or award · Stock Option (right to buy) | +180,000 | 180,000 | ||
| 2026-01-28 | Oki Mark K Chief Financial Officer | Grant or award · Stock Option (right to buy) | +180,000 | 180,000 | ||
| 2026-01-28 | Xinos Jaime Chief Commercial Officer | Grant or award · Stock Option (right to buy) | +180,000 | 180,000 | ||
| 2026-01-28 | Donnelly Craig Chief Operations Officer | Grant or award · Stock Option (right to buy) | +180,000 | 180,000 | ||
| 2026-01-28 | Stewart Richard Alistair Chief Executive Officer | Grant or award · Stock Option (right to buy) | +645,000 | 645,000 | ||
| 2026-01-28 | Wan Jerry Principal Accounting Officer | Grant or award · Stock Option (right to buy) | +70,300 | 70,300 | ||
| 2025-12-04 | Atkisson Erik Chief Legal Officer | Grant or award · Stock Option (right to buy) | +250,000 | 250,000 | ||
| 2025-10-01 | Donnelly Craig Chief Operations Officer | Grant or award · Stock Option (right to buy) | +50,000 | 50,000 | ||
| 2025-09-18 | Oki Mark K Chief Financial Officer | Option exercise | +168,000 | 178,000 | ||
| 2025-09-18 | Oki Mark K Chief Financial Officer | Sale | −50,060 | $2.92 | $146K | 127,940 |
| 2025-09-18 | Oki Mark K Chief Financial Officer | Option exercise · Performance Restricted Stock Unit (PRSU) | −168,000 | 0 | ||
| 2025-09-18 | Stewart Richard Alistair Chief Executive Officer | Option exercise | +297,500 | 358,376 | ||
| 2025-09-18 | Stewart Richard Alistair Chief Executive Officer | Sale | −129,501 | $2.92 | $378K | 228,875 |
| 2025-09-18 | Stewart Richard Alistair Chief Executive Officer | Option exercise · Performance Restricted Stock Unit (PRSU) | −140,000 | 0 | ||
| 2025-09-18 | Stewart Richard Alistair Chief Executive Officer | Option exercise · Performance Restricted Stock Unit (PRSU) | −157,500 | 0 | ||
| 2025-09-04 | Oki Mark K Chief Financial Officer | Grant or award · Performance Restricted Stock Unit | −168,000 | 0 | ||
| 2025-09-04 | Stewart Richard Alistair Chieve Executive Officer | Grant or award · Performance Restricted Stock Unit | −140,000 | 0 |
Page 2 of 36 · 715 trades